tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SOLTF Stock Latest News

Sosei Group Earnings Call Marks Cautious Transition
Company AnnouncementsSosei Group Earnings Call Marks Cautious Transition
12h ago
Nxera Pharma Revamps Board to Strengthen Governance and Growth Strategy
PremiumCompany Announcements
Nxera Pharma Revamps Board to Strengthen Governance and Growth Strategy
2d ago
Nxera Pharma tightens focus as Japan and APAC portfolio powers 2025 growth
PremiumCompany Announcements
Nxera Pharma tightens focus as Japan and APAC portfolio powers 2025 growth
2d ago
Nxera Pharma Slashes Executive Bonuses Following 2025 Results
PremiumCompany Announcements
Nxera Pharma Slashes Executive Bonuses Following 2025 Results
2d ago
Nxera Pharma boosts Japan-APAC portfolio and pipeline as 2025 restructuring sharpens growth focus
PremiumCompany Announcements
Nxera Pharma boosts Japan-APAC portfolio and pipeline as 2025 restructuring sharpens growth focus
2d ago
Nxera Pharma Slashes Executive Bonuses After FY2025 Results to Sharpen Capital Discipline
PremiumCompany AnnouncementsNxera Pharma Slashes Executive Bonuses After FY2025 Results to Sharpen Capital Discipline
2d ago
Nxera Pharma Grows Revenue but Widens Loss on R&D and Finance Costs in 2025
Premium
Company Announcements
Nxera Pharma Grows Revenue but Widens Loss on R&D and Finance Costs in 2025
2d ago
Nxera Pharma books ¥24.3bn non-cash impairment with no impact on consolidated results
Premium
Company Announcements
Nxera Pharma books ¥24.3bn non-cash impairment with no impact on consolidated results
2d ago
Nxera Pharma Swings to Deeper FY2025 Loss but Guides for Strong Profit Rebound in 2026
PremiumCompany Announcements
Nxera Pharma Swings to Deeper FY2025 Loss but Guides for Strong Profit Rebound in 2026
2d ago
Nxera Pharma to Book $1.8 Million Milestone from Centessa Collaboration
PremiumCompany Announcements
Nxera Pharma to Book $1.8 Million Milestone from Centessa Collaboration
3d ago
Nxera Pharma spins out GPCR program to new life sciences-backed company
PremiumCompany Announcements
Nxera Pharma spins out GPCR program to new life sciences-backed company
3d ago
Nxera Pharma’s Insomnia Drug Daridorexant Clears Key Phase 3 Hurdle in South Korea
PremiumCompany Announcements
Nxera Pharma’s Insomnia Drug Daridorexant Clears Key Phase 3 Hurdle in South Korea
27d ago
Nxera Pharma Secures US$3.6 Million Milestone from Centessa Collaboration
PremiumCompany AnnouncementsNxera Pharma Secures US$3.6 Million Milestone from Centessa Collaboration
1M ago
Nxera Pharma Secures Asia-Pacific Rights to Santhera’s Vamorolone for Duchenne Muscular Dystrophy
Premium
Company Announcements
Nxera Pharma Secures Asia-Pacific Rights to Santhera’s Vamorolone for Duchenne Muscular Dystrophy
1M ago
Nxera Pharma Completes ¥5 Billion Buyback of 2028 Convertible Bonds
Premium
Company Announcements
Nxera Pharma Completes ¥5 Billion Buyback of 2028 Convertible Bonds
2M ago
Nxera Pharma Regains Full Rights to Phase 2–Ready Schizophrenia Drug After Boehringer Ingelheim Opts Out
PremiumCompany Announcements
Nxera Pharma Regains Full Rights to Phase 2–Ready Schizophrenia Drug After Boehringer Ingelheim Opts Out
2M ago
Nxera Completes Buyback and Consent Solicitation for Convertible Bonds
PremiumCompany Announcements
Nxera Completes Buyback and Consent Solicitation for Convertible Bonds
2M ago
Nxera Pharma Receives Dividends from UK Subsidiary
PremiumCompany Announcements
Nxera Pharma Receives Dividends from UK Subsidiary
2M ago
Nxera Pharma Initiates Bond Buyback and Consent Solicitation
PremiumCompany Announcements
Nxera Pharma Initiates Bond Buyback and Consent Solicitation
3M ago
Nxera Pharma Launches New Employee Stock Ownership Plan in Japan
PremiumCompany AnnouncementsNxera Pharma Launches New Employee Stock Ownership Plan in Japan
3M ago
Nxera Pharma Announces Strategic Restructuring to Boost Profitability
Premium
Company Announcements
Nxera Pharma Announces Strategic Restructuring to Boost Profitability
3M ago
Nxera Pharma Advances in Metabolic Therapies Amid Financial Challenges
Premium
Company Announcements
Nxera Pharma Advances in Metabolic Therapies Amid Financial Challenges
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >